-
Enrollment Reached in Phase 3 Trials to Test Ublituximab in Relapsing MS
TG Therapeutics has achieved target enrollment in the ULTIMATE I and II Phase 3 trials testing ublituximab (TG-1101) in relapsing MS. Click here to read more.
Have you ever enrolled in a clinical trial? What was that experience like?
-
1 Reply
-
I was in the Phase-3 clinical trial for Avonex, many years ago. Unfortunately, I was on the placebo. Fortunately, the study was so successful that it ended early and I was among those who were first in line to get the “real” stuff.
Log in to reply.